Key facts
- This page summarizes Jay R. Venkatesan's Form 4/A - Amendment filing for Elicio Therapeutics, Inc. (ELTX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Jan 2025, 16:05.
Jay R. Venkatesan - 28 Jun 2024 Form 4/A - Amendment Insider Report for Elicio Therapeutics, Inc. (ELTX)
- Reporting relationship
- Director
- Issuer ticker
- ELTX
- Reported as of
- 28 Jun 2024
- Net transaction value
- +$249,500
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 02 Jan 2025, 16:05:50 UTC
- Original report date
- 02 Jul 2024
- Prior SEC filing
- 29 Dec 2023
- Next SEC filing
- 25 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jay Venkatesan
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Jay R. Venkatesan filed Form 4/A - Amendment for Elicio Therapeutics, Inc. (ELTX) on 02 Jan 2025.
Change
- Previous filing in this sequence was filed on 29 Dec 2023.
- Current net transaction value: +$249,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELTX
transaction
Derivative
Common Warrants
Purchase
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 28 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $5.00
- Footnotes
- F1, F2, F3
ELTX
transaction
Derivative
Pre-Funded Warrants
Purchase
- Transaction value
- $249,500
- Shares
- +50,000
- Change %
- Price
- $4.99
- Shares after
- 50,000
- Date
- 28 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $0.0100
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
Footnote F2
The Common Warrants expire on July 1, 2029.
Footnote F3
On July 2, 2024, the Reporting Person mistakenly filed a Form 4 reporting the acquisition of an additional 150,000 Common Warrants and 150,000 Pre-Funded Warrants. The Reporting Person is not the beneficial owner of such Common Warrants or Pre-Funded Warrants. As of January 2, 2025, the Reporting Person owned only the Common Warrants and Pre-Funded Warrants reported herein.
Footnote F4
Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
Footnote F5
The Pre-Funded Warrants do not have an expiration date.